Revenue Breakdown
Composition ()
No data
Revenue Streams
Harvard Bioscience Inc (HBIO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Instruments, equipment, software and accessories, accounting for 90.2% of total sales, equivalent to $18.58M. Another important revenue stream is Service, maintenance and warranty contracts. Understanding this composition is critical for investors evaluating how HBIO navigates market cycles within the Advanced Medical Equipment & Technology industry.
Profitability & Margins
Evaluating the bottom line, Harvard Bioscience Inc maintains a gross margin of 54.23%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 1.19%, while the net margin is -5.98%. These profitability ratios, combined with a Return on Equity (ROE) of -135.62%, provide a clear picture of how effectively HBIO converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, HBIO competes directly with industry leaders such as MLSS and ZJYL. With a market capitalization of $22.15M, it holds a leading position in the sector. When comparing efficiency, HBIO's gross margin of 54.23% stands against MLSS's 68.67% and ZJYL's 24.31%. Such benchmarking helps identify whether Harvard Bioscience Inc is trading at a premium or discount relative to its financial performance.
